Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function

Summary

Factor XIII is responsible for the cross-linking of fibrin γ-chains in the early stages of clot formation, whilst α-chain cross-linking occurs at a slower rate. Although γ- and α-chain cross-linking was previously shown to contribute to clot stiffness, the role of cross-linking of both chains in determining clot structure is currently unknown. Therefore, the aim of this study was to determine the role of individual α- and γ-chain cross-linking during clot formation, and its effects on clot structure. We made use of a recombinant fibrinogen (γQ398N/Q399N/K406R), which does not allow for y-chain cross-linking. In the absence of cross-linking, intact D-D interface was shown to play a potential role in fibre appearance time, clot stiffness and elasticity. Cross-linking of the fibrin α-chain played a role in the thickening of the fibrin fibres over time, and decreased lysis rate in the absence of α2-antiplasmin. We also showed that α-chain cross-linking played a role in the timing of fibre appearance, straightening fibres, increasing clot stiffness and reducing clot deformation. Cross-linking of the γ-chain played a role in fibrin fibre appearance time and fibre density. Our results show that α- and γ-chain cross-linking play independent and specific roles in fibrin clot formation and structure.

Keywords

Fibrinogen - factor XIII - clot structure

• References

• 1 Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 2001; 936: 291-311.
• 2 Chen R, Doolittle RF. gamma-gamma cross-linking sites in human and bovine fibrin. Biochemistry 1971; 10: 4487-4491.
• 3 Purves L, Purves M, Brandt W. Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (Bitis arietans) acting at cross-linked sites of the gamma-chain. Sequence of carboxy-terminal cyanogen bromide gamma-chain fragments. Biochemistry 1987; 26: 4640-4646.
• 4 Cottrell BA, Strong DD, Watt KW. et al. Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 1979; 18: 5405-5410.
• 5 Matsuka YV, Medved LV, Migliorini MM. et al. Factor XIIIa-catalyzed cross-linking of recombinant alpha C fragments of human fibrinogen. Biochemistry 1996; 35: 5810-5816.
• 6 Sobel JH, Gawinowicz MA. Identification of the alpha chain lysine donor sites involved in factor XIIIa fibrin cross-linking. J Biol Chem 1996; 271: 19288-19297.
• 7 Mockros LF, Roberts WW, Lorand L. Viscoelastic properties of ligation-inhibited fibrin clots. Biophys Chem 1974; 02: 164-169.
• 8 Shen L, Lorand L. Contribution of fibrin stabilisation to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71: 1336-1341.
• 9 Ryan EA, Mockros LF, Stern AM. et al. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J 1999; 77: 2827-2836.
• 10 Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-2826.
• 11 Ariens RA, Philippou H, Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995.
• 12 Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-e99.
• 13 Standeven KF, Carter AM, Grant PJ. et al. Functional analysis of fibrin gamma-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110: 902-907.
• 14 Lord ST, Strickland E, Jayjock E. Strategy for recombinant multichain protein synthesis: fibrinogen B beta-chain variants as thrombin substrates. Biochemistry 1996; 35: 2342-2348.
• 15 Takebe M, Soe G, Kohno I. et al. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterisation, and application to fibrinogen purification. Thromb Haemost 1995; 73: 662-667.
• 16 Weisel JW, Nagaswami C. Computer modeling of fibrin polymerisation kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63: 111-128.
• 17 Abou-Saleh RH, Connell SD, Harrand R. et al. Nanoscale probing reveals that reduced stiffness of clots from fibrinogen lacking 42 N-terminal Bbeta-chain residues is due to the formation of abnormal oligomers. Biophys J 2009; 96: 2415-2427.
• 18 Allan P, Uitte de Willige S, Abou-Saleh RH. et al. Evidence that fibrinogen gamma’ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost 2012; 10: 1072-1080.
• 19 Evans RM, Tassieri M, Auhl D. et al. Direct conversion of rheological compliance measurements into storage and loss moduli. Phys Rev E Stat Nonlin Soft Matter Phys 2009; 80: 012501.
• 20 Shen LL, McDonagh RP, McDonagh J. et al. Fibrin gel structure: influence of calcium and covalent cross-linking on the elasticity. Biochem Biophys Res Commun 1974; 56: 793-798.
• 21 Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-462.
• 22 Collet JP, Moen JL, Veklich YI. et al. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005; 106: 3824-3830.
• 23 Chernysh IN, Nagaswami C, Purohit PK. et al. Fibrin clots are equilibrium polymers that can be remodelled without proteolytic digestion. Sci Rep 2012; 02: 879.
• 24 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 03: 1894-1904.
• 25 Carlisle CR, Sparks EA, Der LC, Guthold M. Strength and failure of fibrin fibre branchpoints. J Thromb Haemost 2010; 08: 1135-1138.
• 26 Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 7195: 1361-1365.
• 27 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371-6374.
• 28 Helms CC, Ariens RA, Uitte de WS. et al. alpha-alpha cross-links increase fibrin fibre elasticity and stiffness. Biophys J 2012; 102: 168-175.